Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Obesity Drug Guidance Should Relax Trial Enrollment Criteria, PhRMA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients with a body mass index exceeding 25, rather than BMI>27, should be allowed in trials, PhRMA says. Revised guidance should also eliminate the need for a weight-loss attempt immediately before enrollment, the association suggests.

You may also be interested in...



Obesity Drug One-Year Data Sufficient For Safety and Efficacy – Cmte

Weight-loss drug trials should include one-year of data on at least 1,500 patients, FDA’s Endocrinologic & Metabolic Drugs Advisory Committee says. Run-in periods prior to clinical trials are unnecessary, committee members agree.

Obesity Drug One-Year Data Sufficient For Safety and Efficacy – Cmte

Weight-loss drug trials should include one-year of data on at least 1,500 patients, FDA’s Endocrinologic & Metabolic Drugs Advisory Committee says. Run-in periods prior to clinical trials are unnecessary, committee members agree.

Bristol Has Appetite For Obesity: Firm To License Solvay Phase I Cannabinoid Antagonist

The companies will jointly develop and commercialize SLV319. Potential inroad into obesity market aligns with Bristol's long-term focus on "high-potential disease areas," company says.

Related Content

Topics

UsernamePublicRestriction

Register

PS059364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel